Atria Investments’s Aimmune Therapeutics AIMT Stock Holding History

Atria Investments’s Portfolio AIMT Stock Details AIMT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q2	–	Sell	-16,237	Closed	-$234K	–	815
2020 Q1	$234K	Buy	16,237 +1,024	+7%	+$26.2K	0.02%	488
2019 Q4	$509K	Buy	15,213 +1,371	+10%	+$38.3K	0.01%	785
2019 Q3	$290K	Sell	13,842 -96	-0.7%	-$1.96K	0.01%	728
2019 Q2	$294K	Buy	13,938 +3,493	+33%	+$71.9K	0.01%	749
2019 Q1	$233K	Buy	10,445 +1,570	+18%	+$37K	0.01%	809
2018 Q4	$212K	Buy	8,875 +1,080	+14%	+$27.9K	0.01%	798
2018 Q3	$213K	Buy	+7,795	New	+$220K	0.01%	915

Other funds holding AIMT

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

EAM

Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return

Fiera Capital (Canada) Montreal, Quebec, Canada $29.2B AUM 20.16% 1-Year Est. Return

RHJA

Rice Hall James & Associates San Diego, California $1.8B AUM 36.16% 1-Year Est. Return

Atria Investments's AIMT Position: Q2 2020 in Review

Atria Investments sold out of Aimmune Therapeutics (AIMT) in Q2 2020, closing a stake of 16,237 shares — an estimated $234K sold.

Atria Investments first reported a position in AIMT in Q3 2018 and held it in 7 quarters. The position peaked at $509K in Q4 2019. 165 funds tracked by Wall St. Rank hold AIMT as of Q2 2020.

Atria Investments reported no remaining Aimmune Therapeutics position as of Q2 2020 after selling out during the quarter.
Atria Investments sold 16,237 Aimmune Therapeutics shares in Q2 2020, an estimated $234K.
Atria Investments first reported a position in Aimmune Therapeutics in Q3 2018 and held it in 7 quarters.
Atria Investments's Aimmune Therapeutics position peaked at $509K in Q4 2019.
165 funds tracked by Wall St. Rank held Aimmune Therapeutics as of Q2 2020.

Based on Atria Investments's 13F filing for Q2 2020, filed 13 Aug 2020.